Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.
Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.
Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.
Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.
Intratumoral, or intralesional, therapies are injected directly into the tumor, but can have systemic effects such that some non-injected lesions demonstrate regression.
Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.
Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.
Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Low-fat Diet and Breast Cancer
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment
- Anti-CD19 CAR-T Cells May Be Safe and Effective in Chronic Lymphocytic Leukemia
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Saturated Fat May Increase Risk of Lung Cancer
- Hyperthermia Plus Chemotherapy May Be Effective in Pancreatic Cancer
- Drug-herb and Drug-drug Interactions in Oncology
- Weight in Adolescence May Predict Colorectal Cancer Risk
- Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL